BRAF and cancer: Using the new data infrastructure of the Swiss Personalized Oncology project of the Swiss Personalized Health Network (SPHN), we evaluated the fate of patients with cancer with non-V600 <i>BRAF</i> mutations in comparison to patients with class 1 mutations.<h4>Patients and methods</h4>In this retrospective observational multicenter study, we have assembled a cohort of 392 patients with class 1 and 154 patients with nonclass 1 <i>BRAF</i> mutations (76 colorectal cancers, 96 lung cancers, 297 melanomas, and 77 other cancers).